Brokerages positive on Alembic Pharma's US growth outlook, weak domestic show still a concern
They expect the company's forthcoming facility launches in the US to lead to a healthy operating leverage.Alembic Pharma plans to launch over 20 products in FY24, with a focus on oral solids, injectables, and derma segments
Neutral Alembic Pharma; target of Rs 710: Motilal Oswal
Motilal Oswal recommended Neutral rating on Alembic Pharma with a target price of Rs 710 in its research report date November 07, 2023.
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Please find enclosed herewith the Intimation dated 9th November, 2023 received from Linkintime India Private Limited, Registrar and Share Transfer Agent. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We enclose herewith the Newspaper Cutting of Extract of Unaudited Financial Results for the quarter and half year ended 30th September, 2023 ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find attached the audio recording.
Alembic Pharmaceuticals Results Earnings Call for Q2FY24
Conference Call with Alembic Pharmaceuticals Management and Analysts on Q2FY24 Performance and Outlook. Listen to the full earnings transcript. Q2FY24 Quarterly & H1FY24 Bi-Annual Result Announced for Alembic Pharmaceuticals Ltd.
Alembic Pharmaceuticals announced Q2FY24 & H1FY24 results: 1. Financial Highlights: - Net Sales grew 8% to Rs 1,595 crore for Q2FY24. - Net Profit for the quarter at Rs 137 crore. - Net Sales grew 13% to Rs 3,081 crore for the H1FY24. - Net Profit for H1FY24 at Rs 257 crore. 2. India Branded Business: - India Branded Business at Rs 577 crore witnessed growth of 5% in Q2FY24 against IPM growth of 7%. - Specialty therapies recorded growth of 10% vis a vis industry growth of 9%. - Performed relatively better than the market in the Antibiotic and Respiratory segments. - Animal Health business recorded growth of 32% over Q2FY23. 3. International Business: - US Generics at Rs 444 crore up by 6% on a YoY basis and by 14% on a QoQ basis. - Ex-US International Formulations grew 17% to Rs 252 crore in the quarter. - Regular exports from both general injectable and oncology plants. 4. API Business: - API business grew 10% at Rs 322 crore in the quarter. - 132 cumulative DMF Filings. Shaunak Amin, Managing Director, Alembic Pharmaceuticals, said, "Despite the challenges of a muted demand in the Antibiotic and respiratory market, it was a satisfactory quarter, backed with a strong performance by our specialty and animal healthcare portfolio. We are confident of returning to an industry-beating growth moving forward." Pranav Amin, Managing Director, Alembic Pharmaceuticals, said, "It was a satisfactory quarter led by growth in all the verticals of the company, in particular Ex-US which grew by 17% and the API business outperformed with a 10% growth during the quarter." Result PDF ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Investor Presentation
PLease find attached the investor presentation ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
PLease find attached ALEMBIC PHARMACEUTICALS LTD. - 533573 - Results 30Th September, 2023
PLease find attached the Results